Is Jianmin Pharmaceutical GroupLtd (SHSE:600976) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zhitong A Share Sale Restriction and Release List | May 24
According to the Zhitong Finance App, the ban on restricted shares of 10 listed companies was lifted on May 24, with a total market value of about 4.486 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, number of restricted shares, external service holdings, 600662 share incentives, 6.3781 million Aixu shares, 600,732 share incentives, 493,000, Jianmin Group, 600,976, share incentives, 21,500, Tongyou Technology 300,302 share incentives, limited sales, 330,000 Xinhe shares, 003016, shares limited circulation 516,800, agricultural biotechnology 6033
Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Shares Lagging The Market But So Is The Business
With a price-to-earnings (or "P/E") ratio of 17.5x Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) may be sending bullish signals at the moment, given that almost half of all companies in China ha
Jianmin Group (600976.SH) announced first-quarter results, net profit of 99.52 million yuan, a year-on-year decrease of 0.04%
Jianmin Group (600976.SH) disclosed its report for the first quarter of 2024. The company achieved 9.7 revenue during the reporting period...
Jianmin Group (600976.SH) will distribute 1.2 yuan per share in 2023. The stock registration date is April 25
Jianmin Group (600976.SH) issued an announcement that the company will implement the 2023 annual equity distribution, distributed per share...
Jianmin Group (600976.SH): The phase II clinical trial of the company's product Tongzheng Granule is in the summary stage
Gelonghui April 16 丨 Some investors asked Jianmin Group (600976.SH) through an interactive platform: How is your company's clinical progress in Tongzheng Granule? How long until launch? Jianmin Group (600976.SH) replied: The second phase clinical trial of the company's product Tongzheng Granule is in the summary stage. There is some uncertainty in the development of new drugs. Investors are kindly requested to pay attention to investment risks.
Jianmin Pharma Gets Nod to Market Asthma Drug
Jianmin Pharmaceutical Group (SHA:600976) obtained approval from China's National Medical Products Administration to market its terbutaline sulfate atomized inhalation product, the company said in a T
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Solid Profits Have Weak Fundamentals
Investors were disappointed with Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlyi
Retail Investors Among Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 8.4% Last Week
Key Insights Significant control over Jianmin Pharmaceutical GroupLtd by retail investors implies that the general public has more power to influence management and governance-related decisions 51%
Jianmin Group (600976.SH): In 2024, the company will continue to build the “Dragon Ball” brand
Gelonghui, March 5 | Jianmin Group (600976.SH) recently said during a survey receiving institutional investors that Longmu is the company's exclusive product, a Class B drug under the National Health Insurance. The 2023 National Health Insurance Catalogue lifted restrictions on the scope of reimbursement for “pediatric rickets,” which will have a positive effect on the promotion of Longmu on the hospital line. In 2024, the company will continue to build the “Longmu” brand, increase accurate advertising and professional brand building; increase refined marketing management, further decline in sales, increase team building and evidence-based medical research, and strive to promote a continuous increase in Longmu's sales revenue
Jianmin Group (600976.SH): Spleen Health and Blood Granules will be the third single product the OTC channel is focusing on
Gelonghui, March 5, 丨 Jianmin Group (600976.SH) recently said during a survey of institutional investors that Jianmin Group () will be the third single product focused on the OTC channel. The product has the effects of strengthening the spleen and stomach, nourishing blood and calming, and is used for children with poor spleen and spleen iron deficiency anemia, and adult qi and blood deficiency iron deficiency anemia; it is a national-based drug type. As the company's exclusive product, we have sorted out the channel and sales model to optimize the value chain. An OTC channel single product created, I hope to have one Good development.
Jianmin Group (600976.SH): Received a total of 59.3834 million yuan in government subsidies
Gelonghui, Feb. 7: Jianmin Group (600976.SH) announced that as confirmed by the financial department, the company and its holding subsidiaries received a total of 59.3834 million yuan in relevant government grants from February 1, 2023 to February 7, 2024, of which 59.5528 million yuan was government subsidy funds related to revenue, accounting for 14.56% of the company's 2022 audited net profit attributable to shareholders of listed companies of 40,75691 million yuan.
Jianmin Pharmaceutical GroupLtd (SHSE:600976) Has A Rock Solid Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Jianmin Group (600976.SH): The traditional Chinese medicine diagnosis and treatment business is an emerging business that the company has continued to cultivate in recent years
Gelonghui, Feb. 5 | Jianmin Group (600976.SH) recently said during a survey reception from institutional investors that the traditional Chinese medicine diagnosis and treatment business is an emerging business that the company has continued to cultivate in recent years and has maintained a good momentum of development. At present, the company has 3 traditional Chinese medicine clinics. Among them, the Hanyang Hall opened in 2018. After 5 years of development, it has begun to take shape. Net profit increased 130% year-on-year in 2022, and the business revenue and profit situation continued to grow in 2023. In March 2023, the company's second TCM center, Hankou, opened and operated, and is now profitable. The third TCM hospital, Wuchang, has entered the trial phase. Not
Jianmin Group (600976.SH): Longmu Bone Nutritional Bar is a new product launched in 2023 for the company's health business
Gelonghui, Feb. 5 | Jianmin Group (600976.SH) recently said during a survey receiving institutional investors that Longmu Bone Nutritional Bar is a new product launched by the company's Big Health Business in 2023. Currently, the sales scale is small, and it is mainly being sold and promoted on online platforms.
Jianmin Group (600976.SH): Overall hospital line products continued to grow in 2023, sales of old products such as spleen health tablets were good
Gelonghui, Feb. 5, 丨 Jianmin Group (600976.SH) recently said during a survey of institutional investors that the company's hospital line products have maintained a continuous growth trend in recent years. The varieties that sold over 100 million yuan in 2022 include Xiaojin capsules, spleen health care capsules, pediatric Baotaikang granules, and estradiol gels; overall hospital line products continued to grow in 2023, and sales of old products such as healthy spleen blood tablets, bowel relief capsules, estradiol gels, etc. were good; sales of new products such as Qirui Weishu capsules were sold at around 70 million yuan, and the release of toxic myotropic factors was better. The small growth rate is faster. Class 1.1 innovative traditional Chinese medicine drug child purple in the second half of 2023
Jianmin Group (600976.SH): OTC channel Bentong capsule sales will be around 100 million in 2023
Gelonghui, January 30丨Jianmin Group (600976.SH) recently said during a survey receiving institutional investors that Bento capsules are the company's exclusive product. Medicare Class B medication have the effects of strengthening the spleen and kidneys, moisturizing the intestines and laxating, and can be used to relieve symptoms of constipation caused by insufficient spleen and kidney deficiency and intestinal gas retention. The hospital channel and OTC channel are sold simultaneously. Among them, the OTC channel achieved rapid growth, mainly due to the small base in the early stages. In 2023, sales of Benton capsules through the OTC channel were around 100 million, and sales of Benton capsules through the hospital channel were stable.
Jianmin Group (600976.SH): In 2024, it will build a dual brand around “Dragon Ball” and “Jianmin”
Gelonghui, January 30丨Jianmin Group (600976.SH) recently said during a survey receiving institutional investors that in 2024, we will build a dual brand around “Longjiao” and “Jianmin”, “Longmin” is positioned as a healthy child growth brand, and “Jianmin” is positioned as a household medicine brand. We will strengthen product matrix construction around brand positioning and continue to strengthen team refinement and fine management. In terms of products, in addition to Longmu, we are also actively cultivating second-tier products: the new OTC channel Bento capsules are growing rapidly this year, mainly because the scale was relatively small in the early stages; spleen strengthening and blood production granules will be the next focus
Jianmin Group (600976.SH): Overall sales of Dragon Mu are good
Gelonghui, January 15, 丨 Jianmin Group (600976.SH) said when surveyed by specific subjects, that the overall sales situation of Dragon Mu is good. The 30-bag Dragonfly sales are basically normal, and the growth rate is slower than the 60-bag Dragon Mu. Mainly, the sales channels for the two products are different. The 30-bag Dragonfly channel mainly covers single pharmacies and small to medium chains, and the 60-bag Dragon Mu mainly covers large KA chains.
Jianmin Group (600976.SH): Spleen Health and Blood Production Granules are a national-based drug type and are the company's exclusive product
Gelonghui, January 15, 丨 Jianmin Group (600976.SH) said in response to a survey of specific subjects that is a national-based drug type. It is an exclusive product of the company. It has the effects of strengthening the spleen and stomach, nourishing blood and calming the mind. It is used for children with poor spleen and spleen iron-deficiency anemia, and iron-deficiency anemia in adults. We have sorted out channels and created a sales model for Spleen Health Pellets, and optimized the value chain. As the next OTC channel item to focus on, we hope to have a good development.
No Data